SEARCH

SEARCH BY CITATION

References

  • 1
    Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut 1997; 40: 4438.
  • 2
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 15: 1029–35.
  • 3
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 4
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003; 124: 91724.
  • 5
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 6018.
  • 6
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2: 54253.
  • 7
    Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355: 73540.
  • 8
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 32333.
  • 9
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC-II trial. Gut (in press).
  • 10
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab is effective in maintenance of clinical response and remission in patients with active Crohn’s disease: results of the CHARM trial. Gastroenterology 2007; 132: 5265.
  • 11
    Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn’s Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005; 129: 80718.
  • 12
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (PRECISE 1). Gastroenterology 2006; 130(Suppl. 2): A107.
  • 13
    Schreiber S, Khalid-Kareemi M, Lawrance I, et al. Certolizumab pegol, a humanised anti-TNF pegylated Fab′ fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (PRECISE). Gut 2005; 54(Suppl.): A82.
  • 14
    Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 19849.
    Direct Link:
  • 15
    Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10: 3338.
  • 16
    Rutgeerts P, Sandborn WJ, Enns R, Hanauer SB, Colombel J, Kent JD. Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn’s disease who had secondary failure to infliximab therapy: results of the GAIN study. Gut 2006; 55(Suppl.): A21.
  • 17
    Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 759.
    Direct Link: